Clinical Trials

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04597359 Phase: Phase 2 Trial Summary: This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surv – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): ECOG-ACRIN Cancer Research Group|National […]

Researching the Effect of Exercise on Cancer

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04589468 Phase: NA Trial Summary: Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

Jump: MR Simulation For Radiation Therapy Master Protocol

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04545957 Phase: Not Applicable Trial Summary: This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of r – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym: JUMP

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04550494 Phase: Phase 2 Trial Summary: This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) d – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04530552 Phase: Phase 2 Trial Summary: This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04506567 Phase: Phase 1|Phase 2 Trial Summary: The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side e – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College […]

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04486755 Phase: Phase 1 Trial Summary: A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, sim – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Maryland, Baltimore Acronym:

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04478279 Phase: Phase 1|Phase 2 Trial Summary: This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in pati – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sapience Therapeutics Acronym:

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04465500 Phase: Phase 2 Trial Summary: This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Virginia Acronym: Prostate005

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer

June 23rd, 2023 | Clinical Trials

NCT Number: NCT04421222 Phase: Phase 1 Trial Summary: This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will recei – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): ESSA Pharmaceuticals Acronym: EPI-7386

Pin It on Pinterest